Navigation Links
UltraPulse® SurgiTouch CO2 Laser System

ProductsUltraPulse® SurgiTouch CO2 Laser System
Company Lumenis, Inc.
Item UltraPulse® SurgiTouch CO2 Laser System
Features 
  • Ability to quickly deliver up to 250 millijoules of energy in one pulse
  • Coldest and cleanest CO2 surgical laser available today
  • The pulsed energy acts like a blend control, allowing the clinician to select the volume of tissue ablation
  • Integrates the 60 Watt char-free pulse energy and the SurgiTouch user interface and scanner system
  • No other CO2 laser matches its ease-of-use, versatility, precision, control, or performance
  • Automatic pre-set starting parameters, by specialty and by application
  • Suggests a delivery device, tailored to meet multiple surgical needs
  • Scans a highly focused laser beam over a predetermined spot size (potentially up to 15mm)
  • Char-free tissue effects in the SurgiTouch and UltraPulse mode
  • Highest pulse energy and average power in the medical laser industry
  • Physician-selectable pulse energy settings (2 to 225mJ)
  • Delivery devices and accessories for every specialty
  • Easy-to-maneuver, compact design and convenient storage
  • Easy-to-use touch screen controls with large control display
    • Description The UltraPulse system's capability to quickly deliver up to 250 millijoules of energy in one pulse allows for powerful single-pulse ablation. This type of high-energy pulse makes the UltraPulse system the coldest and cleanest CO2 surgical laser available today. When the pulse power is combined with the independent adjustment of pulse energy and operating speed, the clinician is given precise control of the laser. The pulsed energy acts like a blend control, allowing the clinician to select the volume of tissue ablation. The average power determines the rate of pulse arrival and controls the overall rate of tissue removal, so tissue effect can be customized at any speed, achieving superior control with reduced potential for charring. The UltraPulse SurgiTouch combines the best in CO2 laser technologies and offers the most innovative approach to laser surgery today. It integrates the 60 Watt char-free pulse energy and the SurgiTouch user interface and scanner system. No other CO2 laser matches its ease-of-use, versatility, precision, control, or performance.
    Info Lumenis, Inc.
    Customer Service: 877-lumenis

    Related medicine products :

    1. UltraPulse SurgiTouch CO2 Laser System
    2. Full Handle Laseredge Stab Blade Knife, 15 blade
    3. Full Handle Laseredge Stab Blade Knife, 15 blade, 3 mm
    4. Full Handle Laseredge Stab Blade Knife, 22.5 blade
    5. Full Handle Laseredge Stab Blade Knife, 45 blade
    6. Full Handle Laseredge Stab Blade Knife, 30 blade
    7. Full Handle Laseredge Crescent Blade Knife, angled bevel up
    8. Full Handle Laseredge Crescent Blade Knife, straight
    9. Full Handle Laseredge Crescent Blade Knife, angled double bevel
    10. Full Handle Laseredge Crescent Blade Knife, angled bevel down
    11. Full Handle Laseredge Implant Blade Knife, 4.0 mm straight
    Spinal Concepts has developed a versatile set of instruments intended to make posterior lumbar interbody fusion procedures precise, simple and quick every time. The Harmony PLIF Instrument Set is the
    Kerrison (Spurling) Laminectomy Rongeur. 15 cm - 6, thick footplate, large handle, 90 up-cutting, 2 mm wide.
    Kerrison (Micro) Laminectomie Rongeur, with ejector. 18 cm - 7 1/8, with thick footplate, small handle, 90 up-cutting, jaws 2 mm wide.
    OSV II Smart ValveTM, Hakim, H-V Lumbar Valve system is the intelligent choice for meeting the complex demands of hydrocephalus shunting. Automatic pressure response causes the valve to adjust automa
    Medicine Products:
    (Date:10/13/2008)...tion of low plasma levels of antioxidants and blue...rtain forms of the eye disease age-related macular...October issue of Archives of Ophthalmology , one ...s vulnerable to the damaging effects of light," th...rticle. "While wavelengths in the UV radiation ran...
    (Date:10/13/2008).../ -- As the first-ever report,by the United Nation...heduled to be presented to Member States today, th...rease in the number of countries it serves.,Accord...o prevent and treat,fistula in over 45 countries i...unched in 2003, it covered 12 countries., The Sec...
    (Date:10/13/2008)...rages Latinos to Get Tested, LOS ANGELES, Oct. 13...t half of all newly diagnosed HIV/AIDS cases,repor...ationally., -- A week of activities aimed at rais...esting to coincide with National Latino AIDS Aware...Our Community, Our Responsibility: Latinos in Acti...
    (Date:10/13/2008)...en, study found , , MONDAY, Oct. 13 (Hea...re your brain shrinks, a new study has found. ,...ot, you,re going to hurt your brain," said Rajesh ...d experimental therapeutics at the Texas A&M H... something we knew, but this is a huge study that ...
    Breaking Medicine News(10 mins):Health News:Sunlight exposure plus low antioxidant levels may place older adults at risk for eye disease 2Health News:Campaign to End Fistula Quadruples In Size, Reaching Over 45 Countries, Says New Report 2Health News:Campaign to End Fistula Quadruples In Size, Reaching Over 45 Countries, Says New Report 3Health News:Nearly Half of Newly Diagnosed HIV/AIDS Cases in Los Angeles County Are Among Latinos 2Health News:Excess Drinking Shrinks the Brain 2
    ...Reports say that the health providers do not treat...spect and they are not provided with correct diagn...cted in more than 1,000 men with prostate cancer a...an 22% felt they were given their diagnosis insens...
    ...A cloud of controversy has surrounded The Thiruvan...aiming that a one-year-old girl who had received a... tested positive for HIV infection. // According ...o is HIV-positive, was given blood, which had been...
    ...Shortness of breath can be a more reliable indicat... finding that such patients have a higher risk of ...diac pain or other symptoms. //The general notion ... cardiac disease has been disapproved by the findi...
    ...Researchers from University of Cape Town, South Af... and treat cervical cancer prevention programs in ...ow resource settings exclusively for developing an...showed that the test and treat program was very mu...
    Other Medicine News:Health News:Prostate cancer patients not happy with health providers 2Health News:Shortness Of Breath A More Reliable Indicator Of High Risk Cardiac Disease 2Health News:Two screen test and treat screening for cervical cancer 2
    (Date:10/13/2008)...n January 2009 and Final Trial ...t. 13 /- Neurobiological,Te...nnounced that following a,meeting with the U.S. Fo...(TM) (ancrod) Phase 3 clinical program for acute i...nd analyze data from its two concurrently,running ...
    (Date:10/13/2008)... Facet Solutions, Inc. today,announced the complet...S,IDE Pilot Study. The results show a 78% reductio...n 80% reduction in Visual Analog Scores (VAS) for,... for Facet Solutions,added, "We are very pleased ...demonstrate significant pain relief but the safety...
    (Date:10/12/2008)...signed for more uniform drug ..., Oct. 12 /- Boston,Scienti...rehensive data from,the TAXUS ATLAS clinical progr... single-arm, historically controlled trials, which...ng Stent System in a variety of,lesions and patien...
    (Date:10/10/2008)...0 /-,XTENT, Inc. (Nasdaq: ...ng-term follow-up data from the CUSTOM I, II and I... Research Foundation,s (CRF) twentieth annual,Tran...g in Washington, DC.,The CUSTOM clinical trials ar...safety and efficacy of the Custom NX(R) drug eluti...
    Breaking Medicine Technology:Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data 2Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data 3Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data 4Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 2Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 3Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 4Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 5Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 6XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week 2Eklin Medical Reports Record Revenues for 2007 3303 1Eklin Medical Reports Record Revenues for 2007 3303 2Eklin Medical Reports Record Revenues for 2007 3303 3Hayes Clinical Labs to Market MedeFiles Proprietary Electronic Medical Record Management Solution to Patients 3301 1Hayes Clinical Labs to Market MedeFiles Proprietary Electronic Medical Record Management Solution to Patients 3301 2Hayes Clinical Labs to Market MedeFiles Proprietary Electronic Medical Record Management Solution to Patients 3301 3Hayes Clinical Labs to Market MedeFiles Proprietary Electronic Medical Record Management Solution to Patients 3301 4Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th 11903 1Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th 11903 2Centene Foundation for Quality Healthcare Awards Grant to Texas Parent to Parent 11901 1Centene Foundation for Quality Healthcare Awards Grant to Texas Parent to Parent 11901 2Centene Foundation for Quality Healthcare Awards Grant to Texas Parent to Parent 11901 3
    ...Analysis Shows Statistically Significant Changes i...alif., March 26, 2007 /PRNewswire-FirstCall/ --,Al...e initial,results from its Phase IIa clinical tria...c patients with acute agitation. The 10 mg,dose of...rial,which was a statistically-significant reduct...
    ...d CAPTURE 2 Findings Suggest Improved Outcomes in ...26, 2007 /PRNewswire-FirstCall/ --,Positive 30-day...tid stenting can be performed with positive result...ience in real-world,(non-clinical trial) settings ...urgery. Interim results from the first 1,500,patie...
    Other Medicine Technology:Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 2Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 3Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 4Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 5Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 6Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and,Effective Treatment to Reduce Risk of Stroke 2Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and,Effective Treatment to Reduce Risk of Stroke 3Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and,Effective Treatment to Reduce Risk of Stroke 4